ArticlePloS one2025
Lower Firmicutes abundance in gut microbiota associated with amyloid-β positivity in older adults in Japan as assessed by positron emission tomography.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- How gut microbiota contribute to neuropsychiatric disorders: evidence from neuroimaging studies.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlzheimer's disease, marked by amyloid-β accumulation, is a leading cause of dementia. Gut microbiota may influence its development by affecting inflammation or amyloid-β metabolism. However, this association is not well studied in older adults in Japan, whose characteristic diet may uniquely impact gut bacteria.
objectiveTo determine the association between the gut microbiota and positron emission tomography (PET)-determined brain amyloid-β positivity in community-dwelling older adults in Japan.
methodsThis cross-sectional study investigated 136 participants aged 68-86 years from Tokyo. Brain amyloid-β was assessed using PET imaging, and gut microbiota were analyzed from fecal samples using 16S rRNA gene sequencing processed with the QIIME2 pipeline. Taxonomic composition was evaluated at both the phylum and genus levels; participants were classified into above- and below-median groups based on the relative abundance of each taxon. Binomial logistic regression adjusted for age, sex, and antibiotic use was conducted to examine the association between bacterial abundance and PET positivity. For genus-level analyses, p-values were further corrected for multiple comparisons. In addition, α diversity (Shannon, Simpson, Observed OTUs) and β diversity (PCoA based on unweighted UniFrac distances, PERMANOVA) were compared between PET-positive and PET-negative groups.
resultsOf the 136 participants, 34.6% were PET-positive for amyloid-β. Firmicutes showed a significant difference: 26.4% PET-positive in the above-median group vs. 42.6% in the below-median group (p for χ² = 0.047). The binomial logistic regression analysis showed that lower Firmicutes abundance was significantly associated with an increased odds of PET positivity (odds ratio and confidence interval: 2.15 [1.03, 4.52]). At the genus level, no taxon remained significant after correction for multiple comparisons. No significant differences were observed in α or β diversity indices between groups.
conclusionA lower abundance of Firmicutes may be associated with amyloid-β accumulation in the brain, linking the gut microbiota to Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.